FDA approve a shared REMS for all transmucosal fentanyl products
20th February 2012
The US Food and Drug Administration (FDA) have approved a shared Risk Evaluation and Mitigation Strategy (REMS) for all Transmucosal Immediate Release Fentanyl (TIRF) products. This shared program has been designed to streamline the REMS process and will allow prescribers and pharmacists to enrol in one shared REMS system for all TIRF products. The branded fentanyl products currently included are; Abstral (sublingual tablet), Actiq (lozenge), Fentora (buccal tablet), Lazanda (nasal spray), Onsolis (buccal soluble film) and Subsys (sublingual spray), the website will be available in March 2012.
- IV carbamazepine authorized in the US
- PCF5+ 2016 pdf available soon!
- Palladone (hydromorphone) SPC updated
- Authorized glycopyrronium oral solution now available in UK
- NICE Consultation: Care of dying adults in the last days of life
- NICE guidance on multimorbidity
- British guideline on management of asthma updated
- SMC accepts diamorphine nasal spray
- Updated Do Not Attempt Cardiopulmonary Resuscitation policy published in Scotland
- Cochrane review: oxycodone for neuropathic pain